logo
How AI Is Helping Cancer Patients: Saving Lives And Money

How AI Is Helping Cancer Patients: Saving Lives And Money

Forbes06-06-2025
Medical technology concept. Medical doctor.
getty
Cancer treatment is costly. The average cost of cancer care in the U.S. is around $150,000 per patient—more than four times the cost of treatment for other common health conditions, according to AARP. The American Cancer Society projected that In 2025, more than 2 million people in the U.S. are expected to be diagnosed with cancer, with over 618,000 deaths projected. With these high costs, artificial intelligence (AI) is offering new solutions that are not only saving lives but also making cancer care more affordable.
Early detection is one of the most effective ways to reduce cancer treatment costs. When cancer is caught in its earliest stages, treatments tend to be less aggressive and more affordable. At The Christ Hospital, AI has significantly improved lung cancer detection.
'Nearly 70% of lung cancer cases are now found at stage I or II, well above the national average of 46%,' said Seth Howard, executive vice president of research and development at Epic. 'In just six months, over 60 patients started treatment earlier, significantly improving their chances of survival.'
By diagnosing cancer earlier, AI allows doctors to offer more cost-effective treatment options, which helps lower the financial burden on both patients and healthcare systems.
ArteraAI is another example of how AI is transforming cancer care. Their AI technology is helping doctors determine which cancer treatments are best for their patients, preventing unnecessary therapies. 'AI is the most transformative tech we've had in a long time,' said Andre, founder of Artera. 'The impact AI has had on the healthcare system is as powerful as computers have had on the healthcare system. With the ArteraAI Prostate Test, we can personalize treatments, reducing unnecessary costs while improving outcomes.'
The ArteraAI Prostate Test is fully reimbursed by Medicare under its established payment rate, meaning no out-of-pocket costs for eligible Medicare patients. This makes prostate cancer care more affordable and reduces financial strain during treatment.
Surgery is often a key part of cancer treatment. Proprio, a company that has developed AI-powered surgical technology, provides surgeons with real-time data during operations, reducing the need for traditional imaging like CT scans and X-rays. This technology allows for faster surgeries, less strain on hospital staff, and quicker recovery times, which ultimately lowers the cost of care for patients.
Another breakthrough demonstrating AI's transformative potential in cancer care is AION Biosystems' TempShield device. A recent study showed that TempShield, an AI-powered wearable thermometer for oncology patients, can reduce mortality rates by an astonishing 90% among cancer patients undergoing chemotherapy and inpatient hospital stays by 79%. This innovation addresses a crucial, yet often overlooked, fact: more than 50% of cancer deaths are preventable because they result from infections like pneumonia rather than cancer itself.
If you spot a temperature spike (and hence an infection) early and treat it, you save lives. TempShield's continuous temperature monitoring provides clinicians with alerts up to 72 hours before symptoms of infection appear, enabling earlier intervention.
'The real danger in cancer care isn't just the disease—it's the complications we miss,' said Sam Barend, CEO of AION Biosystems. 'TempShield is a game-changer: small, simple, and affordable, and it's helping save lives by catching infections before symptoms appear—just like the blood glucose monitor did for diabetes.'
AI is revolutionizing cancer care, not only improving outcomes but also making treatment more affordable. Early detection, personalized treatment, and more efficient surgeries all contribute to lowering the financial burden on patients while providing better care. With innovations like the ArteraAI Prostate Test and TempShield, AI is making cancer care smarter, more accessible, and more cost-effective for patients across the globe. As AI technologies continue to evolve, they will undoubtedly play an even greater role in both saving lives and reducing the financial strain of cancer treatment.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Jim Cramer Says Affirm is Going to $100
Jim Cramer Says Affirm is Going to $100

Yahoo

time34 minutes ago

  • Yahoo

Jim Cramer Says Affirm is Going to $100

Affirm Holdings, Inc. (NASDAQ:AFRM) is one of the stocks Jim Cramer recently discussed. When a viewer called looking for confirmation of Cramer's bullish view on the company, he remarked: 'It's at $72, it's going to $100, okay? Now, I usually don't talk like that except for, I talk like that with Palantir. 72 goes to 100. I say get on board, Affirm. Yes, get on board. Affirm.' Photo by Yiorgos Ntrahas on Unsplash Affirm Holdings, Inc. (NASDAQ:AFRM) provides a payment platform offering point-of-sale financing, merchant commerce solutions, and a consumer app that enables purchases to be paid over time. Cramer commented on the stock in an April episode. He remarked: 'Well, I think the world of Affirm, but it's what I call an earnings stock. In other words, it doesn't really do anything, change direction until you add the earnings. Right now, the direction is down. When we see the company report on May 8th, I think that therefore we could change direction again because I think that there's no doubt Matt Levchin delivers good quarter after good quarter. But then in between, it trades down and you're dealing with that. I don't think it reverses until we get to May 8th.' Since the above comment, the company's stock price has gained over 100%. While we acknowledge the potential of AFRM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Jerry Jones reveals 2010 cancer diagnosis in new documentary
Jerry Jones reveals 2010 cancer diagnosis in new documentary

Yahoo

time38 minutes ago

  • Yahoo

Jerry Jones reveals 2010 cancer diagnosis in new documentary

Jerry Jones reveals he battled cancer in an upcoming Netflix documentary series about the Dallas Cowboys. In an episode of "America's Team: The Gamble and His Cowboys," the 10-part documentary series scheduled to premier next Tuesday, Jones mentions that he underwent cancer treatment "about a dozen years ago." On Wednesday morning, the Dallas Morning News reported that Jones overcame stage 4 melanoma after a decade-long battle beginning with his diagnosis in 2010. "I was saved by a fabulous treatment and great doctors and a real miracle [drug] called PD-1 [therapy]," Jones told the Dallas Morning News. "I went into trials for that PD-1 and it has been one of the great medicines. "I now have no tumors." REVIEW: 'America's Team' Netflix series a fascinating look at Jerry Jones, Cowboys According to the American Cancer Society, PD-1 therapy targets the PD-1 protein on immune cells. PD-1 is a "checkpoint protein" that can prevent immune cells called "T cells" from attacking normal cells. However, some cancer cells have enough of PDL-1, a different protein that bonds with PD-1 and allows it to prevent attacks from the immune system. The goal of checkpoint protein-related therapy is to block PD-1 from bonding with PDL-1, essentially allowing the body's immune system to attack other cells more freely. The aim is to "help the immune system to better find and attack the cancer cells, wherever they are in the body," but it can lead to some brutal side effects as the immune system might attack other, healthy cells in the body. Jones' stage 4 cancer diagnosis means that the cancer cells from his melanoma had spread to other parts of his body, which is what led to his four surgeries surgeries on his lungs and lymph nodes. According to the American Cancer Society, melanoma patients who have had their cancer metastasize to "distant parts of the body, such as the lungs, liver, or skin, or lymph nodes" have a five-year survival rate of 35%. Jones was one of the fortunate survivors of his battle. This article originally appeared on USA TODAY: Cowboys documentary reveals Jerry Jones' cancer diagnosis in 2010

Jim Cramer on ServiceNow: 'It Would Not Be a Stock That I Would Want to Bet Against'
Jim Cramer on ServiceNow: 'It Would Not Be a Stock That I Would Want to Bet Against'

Yahoo

time39 minutes ago

  • Yahoo

Jim Cramer on ServiceNow: 'It Would Not Be a Stock That I Would Want to Bet Against'

ServiceNow, Inc. (NYSE:NOW) is one of the stocks Jim Cramer recently discussed. A caller asked for short-term and long-term guidance for the stock. In response, Cramer said: 'Okay, ServiceNow short term is being hurt by a call out of Melius, and that's by Ben Reitzes, who was saying that these software as a service companies are going to be under pressure because their seat models can be hurt by AI. I think, longer term, ServiceNow has really good AI, and it would not be a stock that I would want to bet against. So, ServiceNow, longer term, I think is fine. Shorter term, I think it's going to be under pressure.' Stock market data showing an upward trajectory. Photo by Burak The Weekender on Pexels ServiceNow, Inc. (NYSE:NOW) provides cloud-based workflow solutions through its AI-powered Now Platform. The company offers tools for automation, analytics, app development, and service management. Cramer discussed the company stock in a June episode as he stated: 'Alright, ServiceNow. Well, we love ServiceNow, okay? ServiceNow is, you know, we've got corporate software that also is AI, okay. It's enterprise software with AI.' While we acknowledge the potential of NOW as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store